Apalutamide Delivers PFS2 Benefit in mCSPC, Regardless of Subsequent Therapy

Wayne Kuznar
Published: Friday, Feb 14, 2020
Neeraj Agarwal, MD, associate professor of medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute

Neeraj Agarwal, MD

Adding apalutamide (Erleada) to androgen deprivation therapy (ADT) reduced the risk of second progression or death (PFS2) by 34% compared with ADT alone in patients with metastatic castration-sensitive prostate cancer (CSPC). The PFS2 benefit occurred regardless of the first subsequent systemic therapy following study treatment, according to a posthoc analysis of the phase III TITAN trial presented at the 2020 Genitourinary Cancers Symposium.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication